

# The global respiratory syncytial virus burden

## A summary of the latest estimates

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRI) in infants and children across the globe. The burden is disproportionately high in low-income country settings. New estimates quantify the RSV ALRI burden at global, regional, and national scales. Herein is a summary of these estimates.

### KEY TAKEAWAYS


- Approximately 30 million episodes of RSV associated ALRI occur annually, more than 90 percent of which occur in developing countries.
- Ten percent of these episodes lead to hospitalization, though many cases in low- and middle-income countries never make it to a health facility.
- More than 100,000 children are thought to die of RSV ALRI every year, with most deaths occurring in low- and middle-income countries.
- The highest childhood RSV ALRI burden occurs during the first year of life when children are most vulnerable.

### GLOBAL RSV ALRI BURDEN AMONG CHILDREN 0 TO 5 YEARS OF AGE

| Burden category  | Reference year  |                         |                        |                        |
|--|---|-------------------------|------------------------|------------------------|
|  | 2015 (Shi et al. 2017)  | 2005 (Nair et al. 2010) | 2015 (GBD 2015)        | 2005 (GBD 2015)        |
| Number of new RSV ALRI episodes                            | 33.1 M (21.6 M–50.3 M)  | 33.8 M                  | 27.3 M                 |                        |
| Number of severe RSV ALRI episodes                         | 6.3 M (2.3 M–18.19 M)   |                         |                        |                        |
| Number of hospital admissions from RSV ALRI                | 3.2 M (2.7 M–3.8 M);<br>1.4 M (1.2 M – 1.7 M) from<br>0–5 months of age   | 3.38 M                  |                        |                        |
| Number of hospital RSV ALRI deaths                         | 59.6 K (48 K–74.5 K);<br>27.3 K (20.7 K–36.2 K) from<br>0–5 months of age |                         |                        |                        |
| Number of RSV ALRI deaths, hospital and community combined | 118,200 (94.6 K–149.4 K)  | 66 K to 199 K           | 36.4 K (20.4 K–61.5 K) | 58.4 K (33.2 K–97.6 K) |

Note: Numbers in parentheses are the 95% confidence intervals.

### ESTIMATED INCIDENCE OF RSV ALRI AMONG CHILDREN < 5 YEARS OF AGE IN DEVELOPING COUNTRIES



Note: National level estimates of RSV ALRI incidence estimated for 132 developing countries. Reference: Shi et al. 2017.

## RSV ALRI BURDEN 0 TO 5 YEARS OF AGE IN DEVELOPING AND INDUSTRIALIZED COUNTRIES (2015)

| Burden category                                 | Developing countries   | Industrialized countries |
|---|------------------------|--------------------------|
| Number of new RSV ALRI episodes                 | 30.5 M (19.5 M–47.9 M) | 2.5 M (1.2 M–5.3 M)      |
| Incidence of RSV ALRI per 1,000 children        | 50.8 (32.4–79.7)       | 35.6 (16.6–76.2)         |
| Incidence of severe RSV ALRI per 1,000 children | 10.2 (3.5–29.9)        | 3 (1.7–5.5)              |
| RSV ALRI hospital admissions                    | 2.6M (2.2 M–3.1 M)     | 344K (285 K–427 K)       |
| RSV ALRI hospital deaths                        | 59.6K (47.8 K–74.3 K)  | 200 (100–2.2 K)          |

Note: Numbers in parentheses are the 95% confidence intervals. Reference: Shi et al. 2017.


## RSV BURDEN IN DEVELOPING COUNTRIES BY NARROW AGE BANDS (2015)

| Burden category                                 | Age 0–27 days     | Age 28 days–<3 months | Age 3–5 months    | Age 6–11 months   | Age 12–23 months  | Age 24–59 months |
|---|-------------------|-----------------------|-------------------|-------------------|-------------------|------------------|
| Incidence of RSV ALRI per 1,000 children        | 40 (2.5–635.7)    | 45.7 (5.9–356.1)      | 99.6 (38.5–257.7) | 98.8 (58.8–166.1) | 79.1 (45.1–138.9) | 13.4 (8.5–20.9)  |
| Incidence of severe RSV ALRI per 1,000 children | 93.4 (11.2–778.3) | 28.5 (1.4–594.7)      | 38.7 (5.7–265)    | 24.7 (11.5–53.2)  | 10.3 (4.6–23)     | 2.8 (1.3–6.2)    |


Note: Numbers in parentheses are the 95% confidence intervals. Reference: Shi et al. 2017.

## RSV ALRI HOSPITALIZATION RATES AND HOSPITAL CASE FATALITY RATES BY NARROW AGE BANDS

RSV ALRI hospitalization rate meta-estimates



RSV ALRI hCFR meta-estimates



Definitions: hCFR = hospital case fatality rate; LIC = low-income countries; LMIC = lower-middle-income countries; UMIC = upper-middle-income countries; HIC = high-income countries. Reference: Shi et al. 2017.

## REFERENCES

- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet*. 2017;390:946-958. Available at: [http://dx.doi.org/10.1016/S0140-6736\(17\)30938-8](http://dx.doi.org/10.1016/S0140-6736(17)30938-8).
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet*. 2010;375(9725):1545-1555. Available at: [https://doi.org/10.1016/S0140-6736\(10\)60206-1](https://doi.org/10.1016/S0140-6736(10)60206-1).
- Global Burden of Disease (GBD) 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1459-1544. Available at: [https://doi.org/10.1016/S0140-6736\(16\)31012-1](https://doi.org/10.1016/S0140-6736(16)31012-1).



[www.path.org](http://www.path.org)

PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at [www.path.org](http://www.path.org).

**STREET ADDRESS**  
2201 Westlake Avenue  
Suite 200  
Seattle, WA 98121 USA

**MAILING ADDRESS**  
PO Box 900922  
Seattle, WA 98109 USA